Effect of cytochrome P450 (CYP) inducers on caffeine metabolism in the rat

被引:1
作者
Kot, Marta [1 ]
Daniel, Wladyslawa A. [1 ]
机构
[1] Polish Acad Sci, Inst Pharmacol, Dept Pharmacokinet & Drug Metab, PL-31343 Krakow, Poland
关键词
rat; liver microsomes; cytochrome P450 induction; beta-naphthoflavone; phenobarbital; pregnenolone; 16; alpha-carbonitrile; ethanol; testosterone hydroxylation; warfarin; 7-hydroxylation; caffeine metabolism;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Our previous studies, carried out using rat cDNA-expressed cytochrome P450 (CYP) isoforms, liver microsomes and specific CYP inhibitors, showed that the 1-N- and 3-N-demethylation of caffeine at a therapeutic concentration was predominantly catalyzed by CYP1 A2 and CYP2C, its 7-N-demethylation was govemed by P450s of the CYP2C subfamily, while its 8-hydroxylation was specifically mediated by CYP1 A2. The present study was aimed at corroborating the above-described results using another experimental model, i.e. a study of caffeine metabolism in the liver microsomes and specific CYP inducers. Animals received one of the following inducers: beta-naphthoflavone (100 mg/kg ip for 4 days), phenobarbital (10 mg/kg for 6 days or 100 mg/kg ip for 4 days), pregnenolone 16 alpha-carbonitrile (100 mg/kg ip for 4 days) or 15% ethanol ( approximate to 11 g/kg in drinking water for 6 days). Sixteen hours after the last dose of an inducer liver microsomes were prepared and the caffeine metabolism and CYP isoform activities (testosterone 2 alpha-, 2 beta-, 6 beta-, 7 alpha-, 16 beta-hydroxylation and warfarin 7-hydroxylation) were investigated. beta-Naphthoflavone (mainly a CYP1A inducer and CYP2C11 inhibitor) potently accelerated the metabolism of caffeine, the effect on 7-N-demethylation being the weakest. Moreover, the influence of P-naphthoflavone on caffeine metabolism was more potent at the substrate concentration of 100 PM than 800 mu M, in particular in the case of 7-N-demethylation and 8-hydroxylation. Pregnenolone-16 alpha-carbonitrile (mainly a CYP3A inducer and CYP2C11 inhibitor) moderately induced 8-hydroxylation only. Phenobarbital (an inducer of CYP2B and other CYPs and a CYP2C11 inhibitor) moderately stimulated the metabolism of caffeine, but practically did not affect 7-N-demethylation. Ethanol (mainly a CYP2E1 inducer) modestly increased the rates of the N-demethylation reactions. The presently obtained data confirm the pivotal role of CYP1 A2 in the metabolism of caffeine, as well as the involvement of CYP3A in the 8-hydroxylation of caffeine and that of CYP2C11 in its 7-N-demethylation.
引用
收藏
页码:296 / 305
页数:10
相关论文
共 28 条
[1]   Constitutive and inducible hepatic cytochrome P450 isoforms in senescent male and female rats and response to low-dose phenobarbital [J].
Agrawal, AK ;
Shapiro, BH .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (05) :612-619
[2]  
BERTHOU F, 1991, DRUG METAB DISPOS, V19, P561
[3]   CAFFEINE INCREASES ITS OWN METABOLISM THROUGH CYTOCHROME P4501A INDUCTION IN RATS [J].
BERTHOU, F ;
GOASDUFF, T ;
DREANO, Y ;
MENEZ, JF .
LIFE SCIENCES, 1995, 57 (06) :541-549
[4]   INTERSPECIES VARIATIONS IN CAFFEINE METABOLISM RELATED TO CYTOCHROME-P4501A ENZYMES [J].
BERTHOU, F ;
GUILLOIS, B ;
RICHE, C ;
DREANO, Y ;
JACQZAIGRAIN, E ;
BEAUNE, PH .
XENOBIOTICA, 1992, 22 (06) :671-680
[5]   The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes [J].
Christensen, M ;
Andersson, K ;
Dalén, P ;
Mirghani, RA ;
Muirhead, GJ ;
Nordmark, A ;
Tybring, G ;
Wahlberg, A ;
Yasar, Ü ;
Bertilsson, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (06) :517-528
[6]   Involvement of CYP3A1, 2B1, and 2E1 in C-8 hydroxylation and CYP 1A2 and flavin-containing monooxygenase in N-demethylation of caffeine: identified by using inducer treated rat liver microsomes that are characterized with testosterone metabolic patterns [J].
Chung, WG ;
Roh, HK ;
Kim, HM ;
Cha, YN .
CHEMICO-BIOLOGICAL INTERACTIONS, 1998, 113 (01) :1-14
[7]   Direct and indirect interactions between, antidepressant drugs and CYP2C6 in the rat liver during long-term treatment [J].
Daniel, W. A. ;
Haduch, A. ;
Syrek, M. ;
Boksa, J. .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 (08) :580-587
[8]  
Daniel WA, 2003, POL J PHARMACOL, V55, P1055
[9]  
Daniel WA, 2003, POL J PHARMACOL, V55, P1045
[10]  
EUGSTER HP, 1993, DRUG METAB DISPOS, V21, P43